Arista Networks and CoreWeave both posted strong revenue growth through Q2 2026, fueled by demand for AI infrastructure, but their profitability profiles diverge sharply.
Arista achieved a 40% net income margin in the quarter, while CoreWeave posted a negative 24% margin and a $626 million net loss, indicating that revenue expansion alone does not guarantee financial health.
Both companies project continued growth into Q3 2026, though CoreWeave's debt-financed expansion model contrasts with Arista's profitable operations.
What happened
Arista Networks reported Q2 2026 revenue of $3.0 billion (quarter ended June 30, 2026), while CoreWeave posted $2.6 billion for the same period. Both companies are expanding quarter-over-quarter, with Arista forecasting Q3 2026 sales of $3.3 billion and CoreWeave projecting at least $3.5 billion.
Why it matters
Both firms are riding strong demand for AI infrastructure—Arista supplies data center networking hardware and software, while CoreWeave provides cloud computing environments and storage. However, profitability diverges sharply: Arista generated a 40% net income margin in Q2 2026, whereas CoreWeave recorded a negative 24% net income margin, posting a $626 million net loss. For investors, this signals that while CoreWeave's revenue scale is catching up, its path to profitability remains uncertain compared to Arista's established financial strength.
What to watch
CoreWeave's Q3 2026 revenue projection of at least $3.5 billion exceeds Arista's $3.3 billion forecast—a milestone in the company's scaling. Both have undertaken recent strategic moves: Arista introduced new network security capabilities and secured long-term memory supply agreements, while CoreWeave expanded its international data center footprint and secured substantial fresh debt financing.
Ask the AI about this article →
Both Arista Networks and CoreWeave are riding accelerating demand for AI infrastructure, but their business models and financial outcomes reflect different strategies. Arista, which designs and distributes specialized networking hardware, software, and support for data centers, has built consistent quarter-over-quarter expansion since Q3 2024—growing from $1.8 billion to $3.0 billion by Q2 2026. CoreWeave, which operates cloud computing environments and storage for AI workloads, has scaled even faster in percentage terms, growing from $583.9 million in Q3 2024 to $2.6 billion by Q2 2026, though from a smaller base.
However, the two companies diverge sharply on profitability. Arista's 40% net income margin in Q2 2026 reflects a lean, asset-light model generating substantial profit on each revenue dollar. CoreWeave's negative 24% margin and $626 million net loss in the same quarter underscore the capital intensity of building and expanding data center infrastructure globally. The body notes that CoreWeave has recently secured substantial fresh debt financing and expanded its international data center footprint—investments that support rapid revenue growth but depress near-term profitability. Arista, by contrast, has focused on securing long-term memory supply agreements and introducing new security capabilities, preserving margins while supporting growth.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Chai, an AI platform for drug discovery, announced a collaboration with Bristol Myers Squibb to use AI for ide…
Hark and AT&T have announced a partnership focused on providing connectivity solutions for future AI devices
John Deere raised its full-year 2026 profit guidance after reporting a quarterly earnings beat driven by stron…
AT&T is deploying open-source AI models to reduce its reliance on Anthropic's commercial services and lower it…
Zayo, a network infrastructure provider, has expanded its partnership with Corning, a materials science compan…
The pharmaceutical industry is increasing investment in artificial intelligence to accelerate drug discovery a…
